TRPV6-Mediated Ca2+ Signaling in Pancreatic Ductal Adenocarcinoma: From Cellular Physiology to Therapeutic Opportunities
Cancers · 21.05.2026 · 18 (10) · 1670
DOI: 10.3390/cancers18101670 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.05.2026. Verfasst von Boshra Yosef und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, University of Szeged, 6720 Szeged, Hungary. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, Albert Szent-Györgyi Research Grant of the Albert Szent-Györgyi Medical School, Albert Szent-Györgyi Medical School, University of Szeged.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type in which therapeutic options are limited, and the disease is characterized by a poor prognosis. In the development of pancreatic cancer, dysregulated Ca2+ signaling plays a key role by regulating proliferation, survival, metabolic adaptation, and tumor–microenvironment interactions. Among the Ca2+ channels, TRPV6 has emerged as a key regulator since this channel is highly selective for Ca2+ and frequently overexpressed in different types of cancers. The aim of this review is to summarize our current knowledge on the structure, regulation, and function of TRPV6, with emphasis on its cell-type specific roles within the pancreas. We describe the mechanisms by which TRPV6-mediated Ca2+ influx activates oncogenic signaling pathways, such as NFAT, AKT/mTOR, and NF-κB, and how this channel plays a role in intra- and extracellular pH regulation. In addition, the clinical relevance and potential contribution of TRPV6 to therapy resistance are discussed. Finally, we review pharmacological strategies and future perspectives regarding TRPV6 in PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacotherapy, University of Szeged, 6720 Szeged, Hungary.
- Translational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, 6720 Szeged, Hungary.
- Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
ORCID-Profile: Viktória Venglovecz
Förderung
- National Research, Development and Innovation Office
- Albert Szent-Györgyi Research Grant of the Albert Szent-Györgyi Medical School
- Albert Szent-Györgyi Medical School, University of Szeged
- University of Szeged Open Access Fund
Zitieren
APA
Yosef, B., & Venglovecz, V. (2026). TRPV6-Mediated Ca2+ Signaling in Pancreatic Ductal Adenocarcinoma: From Cellular Physiology to Therapeutic Opportunities. Cancers, 18(10), 1670. https://doi.org/10.3390/cancers18101670
Vancouver
Yosef B, Venglovecz V. TRPV6-Mediated Ca2+ Signaling in Pancreatic Ductal Adenocarcinoma: From Cellular Physiology to Therapeutic Opportunities. Cancers. 2026;18(10):1670. doi:10.3390/cancers18101670
BibTeX
@article{Yosef2026,
author = {Yosef, Boshra and Venglovecz, Viktória},
title = {TRPV6-Mediated Ca2+ Signaling in Pancreatic Ductal Adenocarcinoma: From Cellular Physiology to Therapeutic Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1670},
doi = {10.3390/cancers18101670}
}
EUVIMED